Gsk (GSK) Payables (2009 - 2026)

Gsk (GSK) has 18 years of Payables data on file, last reported at -$216.2 million in Q3 2026.

• For the quarter ending Q3 2026, Payables changed N/A year-over-year to -$216.2 million; the trailing twelve-month figure through Sep 2026 stood at -$216.2 million (changed N/A YoY), and the FY2025 full-year result was -$24.5 billion, down 8.23% from the prior year.
• Payables was -$216.2 million for Q3 2026 at Gsk, up from -$25.0 billion in the prior quarter.
• In the past five years, Payables ranged from a high of -$216.2 million in Q3 2026 to a low of -$26.1 billion in Q1 2026.
• A 5-year average of -$21.2 billion and a median of -$22.7 billion in 2024 frame the typical range for Payables.
• Across the five-year window, Payables soared 81.62% in 2022 and sank 399.84% in 2023, its largest moves.
• Gsk's Payables stood at -$23.7 billion in 2022, then advanced by 2.34% to -$23.2 billion in 2023, then increased by 1.98% to -$22.7 billion in 2024, then decreased by 7.79% to -$24.5 billion in 2025, then surged by 99.12% to -$216.2 million in 2026.
• Per Business Quant data, the three most recent Payables figures were -$216.2 million in Q3 2026, -$25.0 billion in Q2 2026, and -$26.1 billion in Q1 2026.